Analyst Price Targets — SIBN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 2:07 pm | — | Truist Financial | $21.00 | $17.92 | TheFly | SI-Bone price target raised to $21 from $18 at Truist |
| February 24, 2026 12:24 pm | — | Truist Financial | $24.00 | $15.62 | TheFly | SI-Bone price target raised to $24 from $23 at Truist |
| December 18, 2025 2:15 pm | — | Truist Financial | $23.00 | $19.62 | TheFly | SI-Bone price target raised to $23 from $21 at Truist |
| December 17, 2025 12:28 pm | William Plovanic | Canaccord Genuity | $27.00 | $19.42 | TheFly | SI-Bone price target raised to $27 from $26 at Canaccord |
| December 16, 2025 11:46 am | David Saxon | Needham | $27.00 | $19.16 | StreetInsider | SI-BONE Inc. (SIBN) PT Raised to $27 at Needham, Added To Conviction List |
| December 2, 2025 11:36 am | — | Morgan Stanley | $23.00 | $18.87 | TheFly | SI-Bone price target raised to $23 from $20 at Morgan Stanley |
| October 15, 2025 12:46 pm | Richard Newitter | Truist Financial | $20.00 | $15.27 | TheFly | SI-Bone price target lowered to $20 from $22 at Truist |
| August 11, 2025 11:10 am | Ross Osborn | Cantor Fitzgerald | $25.00 | $15.68 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN) |
| August 6, 2024 7:40 am | Samuel Brodovsky | Truist Financial | $18.00 | $14.04 | TheFly | SI-Bone price target lowered to $18 from $20 at Truist |
| August 6, 2024 7:16 am | David Saxon | Needham | $19.00 | $14.36 | StreetInsider | SI-BONE Inc. (SIBN) PT Lowered to $19 at Needham |
Latest News for SIBN
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and governance foundation for ViCentra's…
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m.…
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Gazprom Neft , the oil arm of Russia's energy giant Gazprom , said on Friday its first-quarter net profit declined by 3.5% year-on-year to 95.8 billion roubles ($1.35 billion).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SIBN.
U.S. House Trading
No House trades found for SIBN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.